There are two highly specific PI3Kα inhibitors, GDC-0032 (Genetech) and BYL719 (Novartis) that have demonstrated superior inhibition of PIK3CA mutant and amplified cell lines as well as tumor xenografts [27, 28]. Here, PIK3CA is linked to neoplasm.